Elevar Therapeutics
Tracked across 1 events · 7 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for…
Impact: Elevar Therapeutics is the central company in this event, receiving FDA conditional acceptance of the Lyrfigtu brand name for lirafugratinib and preparing for a potential commercial launch. The milestone advances its oncology commercialization effort, though final brand acceptance and approval remain pending.
Sep 22, 2026 · 7 articles
85
United States — Food and Drug Administration granted conditional acceptance Elevar TherapeuticsFDA Conditional Acceptance...
60
United States — Food and Drug Administration granted Priority Review Elevar TherapeuticsFDA Conditional Acceptance...
55
United States — Food and Drug Administration accepted new drug application Elevar TherapeuticsFDA Conditional Acceptance...
40
Elevar Therapeutics licensed lirafugratinib Relay TherapeuticsFDA Conditional Acceptance...
ERGEN INTELLIGENCE
Track Elevar Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard